Nuclear magnetic resonance imaging (MRI) has high image resolution and is widely used in the medical field, but it has the problem of inadequate sensitivity. Therefore, contrast material is needed to enhance the image clarity and accuracy of MRI. In order to further improve the cell
resolution of magnetic resonance imaging (MRI), a new contrast agent, BaYbF5/BaGdF5-Tm, Yb, is obtained by using BaYbF5 and BaGdF5 as the main raw materials and using high temperature thermal decomposition method. A layer of polyethylene glycol (PEG) is added to the material
from the point of view of biocompatibility. TEM and XRD are used to characterize the material, and MTT is used to test the cytotoxicity of the material. The material is used in the imaging process of stem cell-Danhong in the treatment of cerebral infarction. Bioluminescence imaging, immunofluorescence
testing and autoradiography are carried out. A large number of tests have confirmed that the material has low cytotoxicity and is similar to the existing contrast agents in MRI imaging. In bioluminescent imaging experiments, using BaYbF5/BaGdF5-Tm, Yb contrast agent can enhance the optical
density of imaging. In autoradiography test, using BaYbF5/BaGdF5-Tm, Yb contrast agent can clearly show the changes of various tissues. In immunofluorescence test, using BaYbF5/BaGdF5-Tm, Yb contrast agent can find more vascular proliferation cells survive. The new contrast agent proposed
in this study can enhance the imaging ability of MRI. Compared with conventional contrast agents, it has higher cell resolution and lower cytotoxicity. It has positive significance for future disease detection in medicine.
Shijie Cao,Leyao Li,Hongwei An,Guobin Mao,Junbiao Dai,Yingxin Ma
Sensitive and accurate detection of interleukin 6 (IL-6) is crucial for the early diagnosis of cerebral infarction to improve patient survival rates. However, the low-abundance of IL-6 in cerebral infarction presents a significant challenge in developing effective diagnosis method. Herein, we studied and analyzed the strong fluorescence property of 4-aminophenol phosphate (APP) and developed an enzyme-linked immunosorbent assay (ELISA) for IL-6 detection. The detection was based on the integration of optical signal change induced by alkaline phosphatase (ALP)-catalyzed APP hydrolysis and ALP-mediated ELISA. The generated colorimetric signal of 4-aminophenol, APP hydrolysis product, was used for ELISA of IL-6 with a detection limit of 0.1 ng/mL, and the visual detection of IL-6 was achieved. The changes in APP fluorescence have a good linear relationship with the logarithm of IL-6 concentration in the range of 0.005 ng/mL to 5.0 ng/mL, with a detection limit of 0.001 ng/mL, which was 100 times lower than that of conventional pNPP-based ELISA. Furthermore, the constructed ELISA effectively distinguished between samples from patients with cerebral infarction and volunteers with non-cerebral infarction, and the severity of symptoms was well distinguished based on IL-6 measurement. The dual-mode ELISA demonstrated high feasibility of low-abundance biomarker detection and displayed good potential for accurate in vitro diagnosis.
危险品化学品经营许可证（带存储）